Psychology & Behavioral Science Active Updated Nov 17, 2026

Is psilocybin turning into real medicine?

Psilocybin's move into the clinic

Where it stands as of Nov 17, 2026

Compass Pathways has completed its FDA application for COMP360 psilocybin in treatment-resistant depression after two positive Phase 3 trials with more than 1,000 participants. Helus Pharma separately announced a positive Phase 3 for HLP003, a psilocin derivative, in 222 adults, with remission of 50.9% versus 18.2% on placebo at week 6. Both sets of results come from the companies, and it is not known whether the FDA will approve either drug or how durable the benefit is.

0 of 2 promises kept, 2 still open

Once taboo, psilocybin is being tested as a fast-acting treatment for depression and suicidal thoughts, with early and surprising signals in advanced dementia.

The story so far

  1. Nov 17, 2026 Latest

    Helus Pharma announced topline results from APPROACH, a Phase 3 trial of HLP003, a deuterated form of psilocin added to a stable antidepressant in 222 adults with major depressive disorder. At week 6, depression scores fell 19.5 points with HLP003 and 11.9 with placebo, a placebo-adjusted difference of 7.6 points, and remission was 50.9% versus 18.2%. Three treatment-related serious adverse events occurred, and the results are company-announced, not yet peer reviewed.

    Today Got Better

  2. Nov 10, 2026

    Psychiatric Times reported that Compass Pathways has completed its FDA new drug application for COMP360 in treatment-resistant depression, following two positive Phase 3 trials with more than 1,000 participants. In the second trial, 39% of people on two 25 mg doses had a clinically meaningful response by week 6 that held through week 26.

    Today Got Better

  3. Nov 8, 2026

    A University of California, Santa Cruz team led by Yi Zuo reported in Nature Neuroscience that in mice psilocybin quickly pushed cortical neurons to form new connections and helped them mature, while also pruning some older ones. The effect depended on a particular group of cortical neurons and differed between healthy and chronically stressed mice, and the researchers could separate the rewiring from a behavioral response commonly linked to psychedelic effects. The study did not test people.

    Today Got Better

  4. Nov 6, 2026

    PsyPost reported that in female mice modeling schizophrenia, a single dose of psilocybin restored sensory filtering for days. PsyPost also reported that psychologists have petitioned to create a psychedelic science division within the American Psychological Association.

    Today Got Better

  5. Nov 4, 2026

    PsyPost reported a preliminary study suggesting that the setting in which psilocybin is taken may shape its effects on the brain. STAT+ separately ran a piece asking who will get the first psychedelic approved.

    Today Got Better

  6. Nov 3, 2026

    Neuroscience News reported that a single dose of psilocybin lacked lasting behavioral effects in mice, and STAT covered the same finding, noting that psilocybin's lasting benefits prove elusive in mice.

    Today Got Better

  7. Nov 1, 2026

    PsyPost and Futurism reported a JAMA double-blind trial of 193 adults with treatment-resistant depression, in which a single dose of a synthetic mebufotenin nasal spray, the compound in Sonoran Desert toad venom, cut depression scores at the 8 and 12 milligram doses. Symptoms eased within a day and the benefit lasted up to eight weeks, and most patients were ready to leave the clinic within two hours, against four to twelve hours of supervised time for psilocybin. Psychopharmacology researcher Chittaranjan Andrade noted the average patient improved only about 30 percent.

    Today Got Better

  8. Oct 28, 2026

    Nature examined why pharma firms are betting billions on psychedelic drugs despite setbacks. PsyPost separately reported a systematic review finding that news coverage of psilocybin often outpaces the science.

    Today Got Better

  9. Oct 25, 2026

    Neuroscience News reported that University of California, Santa Cruz researchers used two-photon microscopy in mice and saw new dendritic spines surge within 24 hours of psilocybin, with the biggest burst in chronically stressed brains. When the team genetically altered serotonin 2A receptors in Layer 5 neurons, structural growth occurred without the head-twitch response, the mouse stand-in for a psychedelic experience.

    Today Got Better

  10. Oct 23, 2026

    PsyPost reported on a Nature study finding that under psilocybin the brain's activity is not random. It forms structured patterns that track what participants are doing and experiencing.

    Today Got Better

  11. Oct 19, 2026

    PsyPost reported a Swedish trial of 35 adults in which a single 25-mg dose of psilocybin lifted depression on a self-report measure from day two, for more than three months. The difference from placebo on the main clinician-rated measure had faded by one year.

    Today Got Better

  12. Oct 17, 2026

    PsyPost reported a small Oregon study testing a cheaper group model of psilocybin therapy for low-income adults in the state's regulated program. Depression scores dropped after two group dosing sessions, but with no comparison group the role of psilocybin itself is unproven.

    Today Got Better

  13. Oct 15, 2026

    PsyPost reported a new study suggesting psilocybin, LSD and 2C-B each leave different fingerprints on the brain. STAT ran an interview in which the Compass Pathways CEO said the company will 'go slow before we go fast'.

    Today Got Better

  14. Oct 13, 2026

    PsyPost reported that the level of brain entropy during a psychedelic trip tracked participants' later gains in insight and well-being.

    Today Got Better

  15. Oct 11, 2026

    Ars Technica reported that Monash researchers scanned 62 psychedelic-naive volunteers given 19 milligrams of psilocybin, without assigning them tasks, and found brain activity that was not quite the chaos long treated as the standard picture of the drug's effect.

    Today Got Better

  16. Oct 6, 2026

    PsyPost reported a small study of 20 people given a high psilocybin dose for alcohol use disorder. The 11 still abstinent at three months had talked more about inner dialogue and changing habits the day after, while those who drank again talked more about sensations and visions.

    Today Got Better

  17. Oct 4, 2026

    PsyPost reported that 20 people with post-treatment Lyme disease had 40 percent lower symptom burden six months after two supported psilocybin sessions, in a study with no control group.

    Today Got Better

  18. Sep 25, 2026

    Researchers at Nanyang Technological University Singapore and Hong Kong Baptist University gave a single dose of psilocybin to mice bred without the Cntnap2 autism-linked gene and found lasting increases in social behavior, with the same durable effect seen even when the mice were anesthetized through the drug's acute phase.

    Today Got Better

  19. Sep 22, 2026

    Compass Pathways' psilocybin therapy COMP360 met its primary endpoint in a second Phase 3 depression trial.

    Today Got Better

  20. Sep 21, 2026

    A double-blind Oxford trial led by Marieke Martens and Robin Carhart-Harris gave 59 depressed patients either two doses of psilocybin three weeks apart or six weeks of daily escitalopram and found both treatments reduced the brain's tendency to read neutral or ambiguous faces and comments as hostile.

    Today Got Better

  21. Sep 11, 2026

    A mouse study published in Science found that giving psilocybin before chemotherapy kept mitochondria moving and functioning inside nerve axons, preventing chemotherapy-induced peripheral neuropathy entirely, with MD Anderson researchers led by Moran Amit and pain researcher Patrick Dougherty connecting chemo's mitochondrial nerve damage to the psychedelic's nerve-protective effect through the serotonin 2A receptor.

    Today Got Better

  22. Aug 30, 2026

    In a small Johns Hopkins pilot trial, two supervised doses of psilocybin cut chronic post-treatment Lyme disease symptoms roughly in half, with depression, sleep trouble and pain still meaningfully improved six months later.

    Today Got Better

  23. Aug 20, 2026

    A five-year Monash University study, the largest single-site psychedelic neuroimaging dataset yet, scanned 62 psychedelic-naive adults with EEG and fMRI before and after psilocybin and found individual brain activity reorganized into patterns tied to each person's actual activity and experience rather than simply dissolving into chaos, led by senior author Adeel Razi.

    Today Got Better

  24. Aug 17, 2026

    University of Pennsylvania researchers Joseph Cichon, Ahmad Hammo and Stephen Wisser gave mice with chronic pain a single injection of psilocybin targeting the anterior cingulate cortex, the shared brain circuit for emotion and pain unpleasantness, and by the next day both pain sensitivity and depression-like withdrawal had reversed, with the effect lasting at least twelve days, the full length of the study.

    Today Got Better

  25. Aug 3, 2026

    In the first US clinical trial of psilocybin-assisted therapy for treatment-resistant PTSD in military veterans, an 11-week Ohio State University protocol pairing therapy with two psilocybin doses produced remission in 9 of 12 participants one month after treatment with no serious adverse events. A separate UCSF study of 25 healthy adults used brain scans to show a single high dose shifts frontal-lobe circuits toward more flexible processing for a full month afterward, helping explain why the effect outlasts the drug.

    Today Got Better

  26. Aug 2, 2026

    A study using the 2024 National Survey Investigating Hallucinogenic Trends, led by Anita Cservenka of Oregon State University, found adults who used psilocybin alongside alcohol reported fewer depressive symptoms than adults who drank but did not use psilocybin, though the observational design cannot establish that psilocybin caused the difference.

    Today Got Better

  27. Jul 31, 2026

    A Stanford team led by postdoctoral scholar Adam Pines and senior author Leanne Williams applied an optical-flow technique borrowed from computer vision to brain scans from four independent studies of LSD, psilocybin and MDMA, and found all three drugs reliably reduce the flow of sensory signals rising into the default mode network, the brain region tied to self-reflection and rumination that runs abnormally in depression and schizophrenia.

    Today Got Better

  28. Jul 22, 2026

    A study led by Robin Carhart-Harris at UC San Francisco and Imperial College London gave 28 healthy adults a single dose of psilocybin and found that the size of the brain entropy spike during the trip predicted both next-day emotional insight and improved well-being a month later, suggesting the psychedelic experience itself, not just the drug in the bloodstream, drives the therapeutic effect.

    Today Got Better

  29. Jul 17, 2026

    Eli Lilly announced it would acquire AtaiBeckley, a psychedelics-focused biotech, marking a major pharmaceutical company's move into the psilocybin treatment space.

    Today Got Better

  30. Jul 8, 2026

    An FDA Phase 2 study across 35 sites and 84 participants found luvesilocin, a compound designed to work like psilocybin's active ingredient, showed rapid improvement in postpartum depression symptoms. The compound is designed to bring psilocybin's potential specifically to the hormonal and neurological context of the postpartum period, where nearly 20 percent of new mothers experience anxiety or depression.

    Today Got Better

  31. Jun 27, 2026

    A report described psilocybin temporarily restoring speech and mobility in a case of advanced Alzheimer's.

    Today Got Better

  32. Jun 17, 2026

    USC launched a clinical trial pairing psilocybin with mindfulness meditation, and a case described a woman in her eighties with advanced Alzheimer's briefly recovering speech after a dose.

    Today Got Better

  33. Jun 14, 2026

    A study reported that a single dose of psilocybin gave months of relief from chronic suicidal thoughts.

    Today Got Better

On the record

The checkable promises in this story, dated the day they were made. A promise is marked kept, slipped or partly met only when a later report says so; past its own date with no report, it reads "no word", which is what silence honestly is.

Pending Jul 8, 2026

Luvesilocin, a psilocybin-like compound, showed rapid improvement in postpartum depression in an FDA Phase 2 study of 84 participants across 35 sites; whether Phase 3 trials confirm the effect size and safety specifically in postpartum patients is the open question.

Reporting in the Today Got Better brief

showed rapid improvement in postpartum depression symptoms in an FDA Phase 2 study across 35 sites and 84 participants

Today Got Better

Pending Nov 17, 2026 · due Dec 31, 2027

Helus expects topline results from its second pivotal trial of HLP003, EMBRACE, in the fourth quarter of 2027.

Helus Pharma, drug developer

Today Got Better

This story moves with the morning letter.

When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.